APOB and coronary artery disorder: Since most of these drug targets demonstrated genetic evidence of CAD lowering, one might draw conclusions from such heterogeneity of triglycerides effects across these lipid-lowering therapies indicative that perhaps triglycerides were less important and that it was cholesterol or lipoprotein particle concentration (indexed, for instance, by apoB concentrations) that mediated these causal effects.